Core Insights - The innovative small molecule analgesic drug YJ2301 developed by Professor Li Fei's team at Nanjing Medical University has successfully transitioned from laboratory to market with a total transaction value of nearly 400 million yuan through a partnership with Jiutian Pharmaceutical [1] - The establishment of the first national university regional technology transfer center in Jiangsu aims to facilitate the commercialization of academic research, having already connected over 50 domestic and international universities and generated a total intended transaction value exceeding 800 million yuan [1][2] Value Discovery - The BioMatch initiative launched in February 2025 aims to actively promote high-potential projects like YJ2301 by facilitating connections between universities and enterprises, moving away from passive approaches to technology transfer [2][4] - The center's proactive model of "active exploration + precise matching" has fostered an innovative atmosphere where universities are encouraged to transfer technologies and companies are willing to engage [2] Value Cultivation - The center provides technical guidance and financial support to help early-stage projects navigate challenges such as target validation and safety research, which are critical for moving from laboratory to industry [3][6] - For the YJ2301 project, the center's concept validation team conducted comprehensive evaluations and provided tailored plans to facilitate technology transfer [3] Value Protection - The center has introduced a "pay after use" model to alleviate concerns regarding intellectual property risks for both universities and enterprises, allowing companies to test technologies without significant upfront investments [7] - This model has led to the collection of over 1,000 patent results from more than 20 universities, with agreed "post-payment" amounts exceeding 100 million yuan, enhancing opportunities for early-stage projects to reach the market [7] Value Realization - The center acts as an intermediary to bridge the gap between academic research and market needs, providing professional support in negotiations and contract management to ensure successful collaborations [8] - The comprehensive service model established by the center encompasses the entire process from original research to large-scale production, significantly enhancing the commercialization of academic innovations in the biopharmaceutical industry [8]

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-094 | 湖南九典制药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决议案的情形。 2、本次股东会不涉及变更以往股东会决议的情形。 一、会议召开情况 （一）会议召开方式：本次股东会采取现场投票表决与网络投票表决相结合 的方式召开 （二）会议召开时间 1、现场会议时间：2025 年 12 月 30 日 14:30 2、网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 12 月 30 日 9:15-9:25，9:30-11:30，13:00-15:00。 ②通过深圳证券交易所互联网投票系统投票的时间为 2025 年 12 月 30 日 9:15-15:00 期间的任意时间。 （三）现场会议召开地点：公司会议室（长沙市浏阳经济技术开发区健康大 道1号） （四）会议召集人： ...

湖南启元律师事务所 关于湖南九典制药股份有限公司 2025年第二次临时股东会的 法律意见书 致：湖南九典制药股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南九典制药股份有限公司 （以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第二次临时股 东会（以下简称"本次股东会"）根据《中华人民共和国公司法》（以下简称"《公 司法》"）《上市公司股东会规则》（以下简称"《股东会规则》"）等中国现 行法律、法规、规章和规范性文件以及《湖南九典制药股份有限公司章程》（以 下简称"《公司章程》"）的相关规定，就公司本次股东会的召集、召开程序、 出席会议的人员资格、召集人资格、表决程序及表决结果等事宜出具本法律意见 书。 为出具本法律意见书，本所律师出席了本次股东会，并核查和验证了公司提 供的与本次股东会有关的文件、资料，同时听取了公司就有关事实的陈述和说明。 本所出具本法律意见书是基于公司向本所保证；公司已向本所提供了为出具 本法律意见书所必需的资料和信息，一切足以影响本法律意见书的事实和资料均 已向本所披露；公司向本所提供的所有资料和信息均真实、准确、完整，不存在 任何虚假记载、误导性陈述或重大遗 ...

| | | 湖南九典制药股份有限公司 关于召开 2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 12 月 12 日，湖南九典制药股份有限公司（以下简称"公司"）在 巨潮资讯网刊登了《关于召开 2025 年第二次临时股东会的通知》（公告编号： 2025-090），公司定于 2025 年 12 月 30 日 14:30 召开 2025 年第二次临时股东 会，现将股东会有关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 12 月 19 日 7、出席对象： （1）截止 2025 年 12 月 19 日下午收市时在中国结算深圳分公司登记在册 的公司全体股东均有权出席本次股东会，也可以以书面形式委托代理人出席会 议和参加表决，该股东代理人不必是本公司股东； （2）公司董事、监事、董事会秘书及其他相关高级管理人员； 3、本次会议的召集、召开符合《中华人民共和国公司法》《深 ...

西部证券股份有限公司 关于湖南九典制药股份有限公司 2025年度持续督导定期现场检查报告 | 保荐人名称：西部证券股份有限公司 被保荐公司简称：九典制药 | | | | --- | --- | --- | | 保荐代表人姓名：江伟 联系电话：0731-84727299 | | | | 保荐代表人姓名：徐飞 联系电话：0731-84727299 | | | | 现场检查人员姓名：江伟、阳欢欢 | | | | 现场检查对应期间：2025年度 | | | | 现场检查时间：2025年12月15日、2025年12月19日 | | | | 一、现场检查事项 现场检查意见 | | | | （一）公司治理 否 | 是 | 不适用 | | 现场检查手段（包括但不限于本指引第三十三条所列）： | | | | （1）对上市公司董事、高级管理人员进行访谈； | | | | （2）现场查看上市公司的主要生产、经营、管理场所； | | | | （3）查阅历次董事会、股东会会议材料；查阅公司章程及各项规章制度； | | | | （4）取得公司股东名册，检查上市公司的控股股东、实际控制人变动情况。 | | | | 1.公司章程和公司治理制 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has rejected 118 drug listing applications over three days, including 13 first-generic products, indicating a trend towards stricter drug approval processes [1][27]. Group 1: Drug Approval Rejections - The NMPA denied applications for several first-generic drugs, including indomethacin gel patches from Jiutian Pharmaceutical and meloxicam nano-crystal injections from Health元药业 [1][27]. - The rejection of these applications poses a risk to pharmaceutical companies that have made significant investments in these products [1][27]. Group 2: Market Impact and Competition - Jiutian Pharmaceutical, known for its core product, the Loxoprofen sodium gel patch, faced a setback with its indomethacin gel patch application, which had a market share of only 0.16% compared to Nipro Pharma's indomethacin patch, which has over 45% market share and annual sales exceeding 110 million yuan [4][10]. - Four companies have submitted applications for the indomethacin gel patch, with three already receiving clinical approval, indicating a competitive landscape [5][10]. Group 3: Other Drug Applications - Other first-generic applications, such as for bilastine oral solution and brivaracetam orally disintegrating tablets, were also rejected, reflecting the stringent review process [1][27]. - The market for amlodipine besylate, a cornerstone drug for hypertension, remains strong, with sales exceeding 3.6 billion yuan in 2024, despite the influx of generic competitors [11][14]. Group 4: Future Opportunities - The failure of Jiutian Pharmaceutical and Dongyangguang Pharmaceutical in their respective applications highlights the need for companies to focus on quality and clinical needs rather than merely following trends in drug formulation [27]. - The approval of alternative formulations, such as the dry suspension and orally disintegrating tablets, suggests that there are still opportunities for innovation in the market [20][21].

人民财讯12月18日电，九典制药（300705）12月18日在机构调研时表示，公司目前正在全面转型创新药 研发，采用"多个研发中心+多种药物形式+多种合作模式"策略迅速布局创新药。公司同时在中部地区 和长三角布局创新药研发中心，既利用中部地区丰富的临床资源和研发成本优势，又利用长三角区域优 势，建立双中心的创新药研发平台。 ...

Group 1: Product Matrix and Market Position - The company has established a clear and advantageous external product matrix, with significant exclusive and medical insurance advantages in key varieties. Approved products include: Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, Anti-inflammatory Pain Relief Patch, Lidocaine Gel Patch, Strong Waist and Bone Strengthening Patch, and Daiwen Moxibustion Patch [2] - The Ketoprofen Gel Patch is a key exclusive product with significant market competitiveness, while the Daiwen Moxibustion Patch holds both traditional Chinese medicine exclusivity and medical insurance exclusivity, showcasing distinct advantages [2] Group 2: Brand Development Strategies - The company has implemented a series of systematic and innovative measures to enhance brand influence and market recognition, including expanding into retail pharmacies and online platforms [3] - A brand upgrade event was held on December 6, 2025, introducing the "JiuDian Pain Relief Expert" symbol and the slogan "Change to JiuDian for Pain Relief Patches," aimed at addressing consumer pain points and enhancing brand communication and market competitiveness [3] Group 3: Sales and Procurement Expectations - The 11th batch of national centralized procurement results will be executed nationwide starting February 2026, with procurement cycles lasting until December 31, 2028 [3] - The company is optimistic about the market prospects for the Ketoprofen Gel Patch, which was approved for listing in 2023 and successfully entered the national medical insurance directory [3] Group 4: Innovation in Drug Development - The company is undergoing a comprehensive transformation towards innovative drug research and development, utilizing a strategy of multiple R&D centers and various drug forms [4] - Two innovation drug R&D centers are being established in central and Yangtze River Delta regions, leveraging local clinical resources and cost advantages [4] - The company is focusing on various tumor and chronic disease indications, employing small molecule drugs, peptide drugs, PDC, and ADC formats [4] Group 5: New Drug Advantages - The newly introduced small molecule pain relief innovative drug YJ2301 is designed to overcome limitations of existing neurogenic pain medications, such as limited efficacy and significant side effects [4] - Clinical pre-research data for YJ2301 shows superior pain relief effects and the potential to address issues like drowsiness and tolerance, providing a new solution for neurogenic pain management [4]

Core Viewpoint - Jiutian Pharmaceutical has received approval from the National Medical Products Administration to withdraw its drug registration application for indomethacin gel patch due to the need for further improvement of related experimental data [1] Group 1 - The company announced the withdrawal of its drug registration application for indomethacin gel patch on December 17 [1] - The decision to withdraw the application was made after communication with the National Medical Review Center [1] - The company plans to supplement and improve the relevant research before restarting the registration application process [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的《药品注册申请终止通知书》，同意公司撤回吲哚美辛凝胶贴 膏药品注册申请，现将相关信息披露如下： 一、药品的基本信息 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-092 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于撤回药品注册申请的公告 功能主治：用于以下疾病及症状的消炎、镇痛：骨关节炎、肩周炎、肌腱及 腱鞘炎、腱鞘周围炎、肱骨外上髁炎（网球肘）、肌肉痛、外伤所致肿胀、疼痛。 二、药品的研发情况 吲哚美辛凝胶贴膏于 2020 年 2 月获得国家药品监督管理局临床试验批准， 2023 年 11 月完成Ⅲ期临床试验并取得总结报告，2023 年 12 月公司向国家药品 监督管理局提交了上市许可申请并获得受理。 因该药品需进一步完善相关试验数据，经公司与国家药品审评中心沟通后， 决定撤回注册申请，后续公司将补充完善相关 ...